Erudio Healtherudio.com
Clinical trial · no report yet · Early phase 1
PROMETEO trial: what clinicians have said so far
Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer
- NCT03802604 ↗
- Completed
- SOLTI Breast Cancer Research Group
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on PROMETEO (talimogene laherparepvec plus atezolizumab in residual HER2-negative breast cancer after neoadjuvant chemotherapy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PROMETEO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 11 posts on X | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- Combination of Talimogene Laherparepvec With Atezolizumab in Patients With Residual Breast Cancer After Standard Neoadjuvant Multi-agent Chemotherapy (PROMETEO TRIAL)
- Phase
- Early phase 1
- Status
- Completed
- Conditions
- Breast Cancer
- Interventions
- Talimogene laherparepvec; Atezolizumab
- Arms
- Talimogene laherparepvec + Atezolizumab · Experimental
- Enrollment
- 28
- Primary outcomes
- Rate of residual cancer burden class 0 and 1 (RCB0/1)
- Sponsor
- SOLTI Breast Cancer Research Group with Amgen, Roche Pharma AG
- Start
- Dec 10, 2018
- Primary completion
- Apr 27, 2022
- Results posted
- No
- Registry record
- NCT03802604 · updated Sep 9, 2025
Publications
linked from the registry- Pascual T, Vidal M, Cejalvo JM, Vega E, Sanfeliu E, Villacampa G, Ganau S, Parreno AMJ, Zamora E, Miranda I, Delgado A, Bermejo B, Segui E, Braso-Maristanty F, de la Cruz-Merino L, Juan M, Galvan P, Gonzalez-Farre X, Chillara S, Villagrasa P, Pfefferle AD, O'Connell CE, Ferrero-Cafiero JM, Oliveira M, Perou CM, Prat A. Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO). Nat Commun. 2026 Feb 16;17(1):2817. doi: 10.1038/s41467-026-69222-5. PubMed 41698899
- Pascual T, Cejalvo JM, Oliveira M, Vidal M, Vega E, Ganau S, Julve A, Zamora E, Miranda I, Delgado A, Bermejo B, la Cruz-Merino L, Juan M, Ferrero-Cafiero JM, Canes J, Gonzalez X, Villagrasa P, Prat A. SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future Oncol. 2020 Aug;16(24):1801-1813. doi: 10.2217/fon-2020-0246. Epub 2020 Jul 7. PubMed 32633563